2026-08-14 · CagriSema, cagrilintide, semaglutide, amylin, GLP-1, REDEFINE, Novo Nordisk, obesity pharmacology, investigational drugs

What is CagriSema?

CagriSema is an investigational once-weekly subcutaneous injection from Novo Nordisk that combines two peptides in one delivery: cagrilintide 2.4 mg, a long-acting amylin receptor agonist, plus semaglutide 2.4 mg, the same molecule sold as Wegovy and Ozempic. The combination targets two independent satiety pathways at once — GLP-1 (semaglutide) and amylin (cagrilintide) — which is why the weight-loss magnitude in the REDEFINE-1 Phase 3 trial exceeded what either component produced alone. It is not FDA-approved for any indication as of August 2026.

When will CagriSema be FDA-approved?

Novo Nordisk has publicly guided FDA regulatory submission in the 2026 window based on the REDEFINE-1 and REDEFINE-2 Phase 3 readouts (both 2025). Under a standard 10-month FDA review, the earliest realistic obesity-indication approval decision lands in Q3–Q4 2026, with commercial pharmacy availability most likely Q1–Q2 2027. No specific date has been publicly committed. Applying the semaglutide-STEP-to-Wegovy analog (Phase 3 readouts 2018–2020, approval June 2021), an 18-to-30-month runway from readout to shelf is the historical pattern. Any Phase 3 safety signal or manufacturing scale-up delay can extend the timeline.

Is CagriSema better than Wegovy or Zepbound?

It depends on what 'better' means. On weight-loss magnitude, the REDEFINE-1 topline (roughly 22.7 percent at 68 weeks) is meaningfully above Wegovy's roughly 14.9 percent in STEP-1 and modestly above Zepbound's roughly 20.9 percent in SURMOUNT-1. Cross-trial comparisons across separate populations always overstate the certainty of the difference, and no head-to-head trial exists yet — REDEFINE-4 (a planned CagriSema-versus-tirzepatide head-to-head) is anticipated to read out in 2026. For readers whose target is 10 to 15 percent loss, Wegovy already delivers and is on shelves today; for readers who need more than 20 percent, CagriSema will be worth the conversation with an obesity-medicine clinician once approved.

Can I buy compounded CagriSema in 2026?

No — not legally, and not safely. CagriSema is a proprietary Novo Nordisk fixed-dose combination, and the individual peptides in this formulation are patent-protected. Cagrilintide has never been FDA-approved for any indication, has never been on the FDA drug-shortage list, and has no 503A or 503B compounding pathway. Any product sold in 2026 as 'compounded CagriSema' — including 'DIY cagri-sema stacks' assembled from separately-sourced compounded semaglutide plus research-chemical cagrilintide — is illegally compounded or research-chemical peptide, has not been tested for identity, sterility, potency, or dosing accuracy, and has produced reports of hospitalization. Waiting for the FDA-approved product is the only safe route.

What is cagrilintide and how is it different from semaglutide?

Cagrilintide is a long-acting amylin receptor agonist. Amylin is a hormone co-secreted with insulin from pancreatic beta cells; it slows gastric emptying, suppresses glucagon secretion, and produces meal-related satiety through amylin receptors in the brain — a separate satiety pathway from GLP-1. The first commercial amylin analog, pramlintide (Symlin, FDA-approved 2005 for type 1 and type 2 diabetes), required three daily injections and never gained wide use. Cagrilintide's half-life is roughly 8 days, which allows once-weekly dosing and enables the fixed combination with weekly semaglutide. Combining the GLP-1 pathway (semaglutide) and the amylin pathway (cagrilintide) is the mechanistic novelty of CagriSema.

Will CagriSema cause more nausea than Wegovy?

The REDEFINE-1 side-effect profile was broadly similar to Wegovy titration. Roughly 80 percent of CagriSema patients reported at least one GI event across 68 weeks (nausea, vomiting, diarrhea, or constipation), which is comparable in magnitude to the semaglutide 2.4 mg arm in the same trial and to the STEP-1 baseline for Wegovy. Discontinuation for GI intolerance was approximately 5 percent, again similar to the semaglutide-alone arm. In principle, adding amylin (which independently slows gastric emptying) on top of GLP-1 could compound the GI burden, and readers who have already struggled with Wegovy or Zepbound nausea should assume the same or slightly worse tolerability with CagriSema.

How much will CagriSema cost when it launches?

Nothing has been announced because the drug is not yet approved. Pricing is likely to anchor to the current second-generation reference range: Wegovy lists at roughly 1,349 dollars per month in 2026 and Zepbound at roughly 1,059 dollars per month, with manufacturer direct-to-consumer cash channels (NovoCare, LillyDirect) available at roughly 349 to 499 dollars per month. A CagriSema list price in that same 1,000 to 1,400 dollars per month band is the reasonable class-anchored expectation, likely with a NovoCare direct-cash program at a discount. Insurance coverage will follow the same fault lines the class faces today — inconsistent commercial coverage, statutory Medicare Part D exclusion for anti-obesity drugs, and prior authorization with BMI criteria.

Should I switch from Wegovy to CagriSema when it's available?

Only if Wegovy has plateaued short of your goal. In REDEFINE-1, CagriSema produced roughly 6.6 percentage points more weight loss than semaglutide 2.4 mg alone (22.7 percent versus 16.1 percent), and about 40 percent of CagriSema patients hit 25 percent or more weight loss compared to about 16 percent on semaglutide alone. That is a real magnitude difference. But if you are on Wegovy or Zepbound, tolerating it, and hitting your goal, the incremental benefit of switching may not justify the cost, side-effect risk, or access friction. The conversation belongs with an obesity-medicine clinician who knows your response history.

CagriSema for Weight Loss: What Novo’s GLP-1 + Amylin Combo Is, and Why You Can’t Buy It Yet

CagriSema is not FDA-approved and is not commercially available as of August 2026 — no legitimate pharmacy, clinic, or telehealth platform can sell it to you. Any “compounded CagriSema” or “DIY cagri-sema stack” being sold in 2026 is either counterfeit, illegally compounded, or a research-chemical peptide that has never been tested for human sterility, purity, or dosing accuracy — do NOT use these products (see compounded semaglutide and tirzepatide safety for what’s actually in those vials). This page explains what CagriSema is, what the REDEFINE Phase 3 evidence shows, when a legitimate FDA-approval decision is realistic, and how it fits alongside currently-approved drugs like Wegovy, Zepbound, and the investigational retatrutide — the other high-magnitude pipeline drug covered in the next generation weight loss drugs pillar.

What CagriSema actually is

CagriSema is Novo Nordisk’s investigational fixed-dose combination of two peptides in a single once-weekly subcutaneous injection: cagrilintide 2.4 mg (a long-acting amylin receptor agonist) plus semaglutide 2.4 mg (the same molecule sold as Wegovy for chronic weight management and Ozempic for type 2 diabetes). The 2.4 mg + 2.4 mg dose is the combination evaluated in the pivotal REDEFINE-1 Phase 3 obesity trial. It is delivered as a single weekly injection using a Novo pen device — not two separate shots — and the dose is fixed rather than titrated across a range.

The distinguishing feature is that CagriSema engages two independent satiety pathways at once. Semaglutide activates the GLP-1 receptor system familiar from every drug in the Ozempic/Wegovy/Rybelsus family. Cagrilintide activates amylin receptors in the brain, adding a separate meal-related satiety signal that GLP-1 drugs alone do not produce. The mechanistic bet — supported by Enebo 2021 (The Lancet) Phase 1b data and confirmed in REDEFINE-1 — is that two complementary satiety mechanisms produce additive weight loss beyond what either component achieves alone. Novo is also pursuing a single-molecule alternative to the two-peptide CagriSema combination — amycretin engineers amylin and GLP-1 activity into one peptide sequence rather than co-administering two, and Phase 2 programs for both a weekly subcutaneous and a daily oral formulation are now underway with 2027 readouts expected. For the broader map of what the incretin class does and how single-, dual-, and triple-receptor drugs compare, see the GLP-1 weight loss overview.

How amylin works (and why it’s back after 20 years)

Amylin is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells in response to meals. Its physiological role is to complement insulin: amylin slows gastric emptying, suppresses postprandial glucagon secretion (which prevents inappropriate hepatic glucose output after eating), and produces meal-related satiety via amylin receptors in the area postrema of the brainstem. This is a fundamentally different signaling axis from GLP-1 — different receptor, different neural circuit, additive appetite effect. The mechanism is reviewed in Hay 2015 (Pharmacological Reviews).

The first commercial amylin analog was pramlintide (Symlin), FDA-approved in 2005 for insulin-treated type 1 and type 2 diabetes. Symlin never gained wide use for two reasons. First, its short half-life required three separate injections per day, taken before meals — a burden most patients would not sustain. Second, when combined with mealtime insulin, it produced a meaningful hypoglycemia signal that required insulin dose reduction. Amylin as a satiety hormone was proven; amylin as a practical therapy was not.

Cagrilintide changed that calculus. It is an engineered long-acting amylin analog with a half-life of roughly 8 days, enabling once-weekly subcutaneous dosing that matches semaglutide’s cadence. Enebo 2021 (The Lancet, Phase 1b) established the combination’s tolerability and dose-ranging in humans, and Aroda 2024 (Diabetes Care, CagriSema mechanism review) synthesized the current understanding of the two-pathway satiety architecture. Amylin’s hypoglycemia signal in the original pramlintide trials was driven by concurrent mealtime insulin, not by amylin itself; in non-diabetic populations and in the REDEFINE-1 obesity population, cagrilintide did not produce clinically meaningful hypoglycemia. The amylin-only development path that cagrilintide monotherapy pioneered is now carried by Zealand Pharma’s petrelintide (ZP8396) — the only pure amylin analog still in active Phase 2 obesity development, positioned as the “amylin without the GLP-1” option for patients who cannot tolerate the GLP-1 tolerability burden.

REDEFINE Phase 3 data

The REDEFINE program is Novo Nordisk’s Phase 3 development set for CagriSema. Two primary readouts have been published; two more are anticipated. The trial table below anchors the current-and-pending evidence base.

The response-rate detail from REDEFINE-1 matters as much as the mean. Roughly 40.4 percent of CagriSema patients achieved 25 percent or more weight loss, compared with about 16.2 percent on semaglutide 2.4 mg alone — a 2.5-fold difference in the “high responder” tail. That tail is what makes CagriSema a candidate for readers whose weight-loss target sits above what Wegovy alone typically delivers. REDEFINE-4 will provide the first head-to-head comparison against tirzepatide, and REDEFINE-3 is the cardiovascular outcomes trial that would eventually unlock a Medicare Part D pathway on the same door Wegovy walked through under SELECT.

CagriSema vs Wegovy vs Zepbound vs retatrutide

The 2026 high-magnitude obesity-drug landscape is easier to read with the four leading options side by side. The comparison below is between separate trials with different populations and durations — no head-to-head CagriSema-versus-tirzepatide-versus-retatrutide trial exists yet — but it establishes the current-and-pipeline hierarchy.

Two takeaways matter. First, adding pathways adds magnitude, but the increment is not linear — cagrilintide alone (−11.8%) and semaglutide alone (−16.1%) do not add to −27.9% when combined; they add to −22.7%. Second, “highest magnitude” and “reaches patients first” are different columns. Orforglipron is likely first; retatrutide is highest magnitude on paper; CagriSema is the highest magnitude with completed Phase 3 obesity data.

Why not just take semaglutide alone?

This is the most-asked question and it deserves a direct answer. In REDEFINE-1, the semaglutide 2.4 mg arm — the same dose and molecule as Wegovy — produced −16.1 percent at 68 weeks. The CagriSema arm produced −22.7 percent. The incremental benefit of adding cagrilintide on top of semaglutide is roughly 6.6 percentage points of mean weight loss and a 2.5-fold increase in the proportion of patients achieving ≥25 percent loss (40.4 percent versus 16.2 percent). Those are real, clinically meaningful differences.

Whether that increment justifies the trade-off depends on your target. If you need to lose 10 to 15 percent of starting body weight — a magnitude that meaningfully improves cardiometabolic risk for most readers — Wegovy already delivers that today, is on formulary at most insurers that cover obesity drugs, and does not require waiting until 2027. If you need to lose more than 20 percent, or if you have plateaued on maximum-dose Wegovy short of your goal, CagriSema (or Zepbound today, or retatrutide when approved) is where the additional magnitude lives. The right conversation is with an obesity-medicine clinician who knows your response history, not a blanket “always switch” or “never switch” answer.

Expected side-effect profile

The REDEFINE-1 safety picture was broadly consistent with the GLP-1 class expectations, with no unexpected class-outside signals. The table below summarizes the five side-effect categories most patients will want to weigh, based on the published REDEFINE-1 topline.

Class-wide GLP-1 warnings will almost certainly carry to the eventual CagriSema label: personal or family history of medullary thyroid carcinoma and MEN2 syndrome contraindications, pancreatitis warning, gallbladder-disease monitoring, and pregnancy contraindication. For the gallbladder and pancreatitis picture specifically, see gallstones and weight loss and pancreatitis and weight loss.

Expected FDA-approval timeline and pricing

No specific approval date is publicly committed, and any date-certain answer online is speculation. What can be said honestly, using the semaglutide-STEP-to-Wegovy analog (Phase 3 readouts 2018–2020, approval June 2021 — roughly 3 years from Phase 3 start to shelf), is this: the earliest realistic FDA-approval decision for CagriSema lands in Q3–Q4 2026, with commercial pharmacy availability most likely Q1–Q2 2027. Any Phase 3 safety signal or manufacturing scale-up delay can extend the timeline by 12 to 24 months.

Pricing is unannounced. If CagriSema anchors to the current second-generation band, expect a US list price in the roughly 1,000 to 1,400 dollars per month range — comparable to Wegovy’s roughly 1,349 dollars per month in 2026 — with a NovoCare direct-to-consumer cash channel available at a discount. Insurance coverage will follow the same fault lines the class faces today: inconsistent commercial-plan coverage for obesity drugs (many employer plans exclude the class entirely), prior authorization with BMI criteria and documented lifestyle-attempt evidence, and statutory Medicare Part D exclusion for anti-obesity drugs. The REDEFINE-3 cardiovascular outcomes readout in 2027–2028 is the equivalent of the SELECT trial for Wegovy — a positive CVOT would open a Medicare pathway that the obesity-only indication cannot. For the full 2026 pricing table and coverage landscape across the class, see GLP-1 cost and insurance and weight loss injections near me.

Compounded “CagriSema” — the safety warning

This is the most important section of the article. Four hard facts govern the compounded-CagriSema picture in 2026, mirroring the compounded-retatrutide landscape:

1. CagriSema is a proprietary Novo Nordisk fixed-dose combination. The individual peptides in this formulation — cagrilintide and semaglutide at the 2.4 mg + 2.4 mg dose — are patent-protected in this combination. Novo Nordisk does not sell either active ingredient to compounding pharmacies for this use.
2. Cagrilintide has no legal 503A or 503B compounding pathway. The 503A/503B compounding routes require either an FDA drug-shortage listing (which briefly covered compounded semaglutide and tirzepatide in 2022 to 2024 during genuine shortages) or an approved active ingredient. Cagrilintide has never been approved, has never been on the shortage list, and has no legal basis for compounding.
3. “DIY cagri-sema stacks” are dangerous. Anecdotal reports circulating in 2026 describe patients combining separately-sourced compounded semaglutide plus research-chemical cagrilintide in home-mixed injections. Combined peptide sterility, endotoxin contamination, and dosing errors from this practice have produced hospitalizations. Do not do this.
4. No regulator tests these products. The compounded-semaglutide analytical work (Rubino 2023, JAMA) documented mislabeled potency, subpotent product, wrong salt forms, and bacterial contamination in gray-market vials. Compounded cagrilintide, being fully outside any legal pathway, has even less oversight.

The practical translation: any dose of any vial labeled “CagriSema” or “cagrilintide” purchased from a non-Novo source in 2026 is an injection of unknown material at an unknown dose. It is not the intervention that produced the 22.7 percent REDEFINE-1 signal. It is outside every safety-monitoring system that governs approved drugs. The correct answer for a reader who wants CagriSema is to wait for the FDA-approved product. For the full 2026 enforcement landscape and how to evaluate a legitimate compounding pharmacy, see compounded semaglutide and tirzepatide safety and weight loss drug safety.

Who CagriSema will likely fit when approved

The Phase 3 population and mechanism give a reasonable projection of who a future CagriSema prescription will fit — and who it will not.

What to do while waiting for CagriSema

The honest recommendation for most adults with obesity and a candidate diagnosis for pharmacotherapy in 2026 is: do not wait. A four-step protocol makes the wait — or the decision not to wait — as productive as possible.

1. Optimize a currently-approved GLP-1. Wegovy (roughly 15% weight loss) and Zepbound (roughly 21%) are excellent tools that deliver durable weight loss today. Starting therapy now is not a lock-in; switching to CagriSema at approval is straightforward. If you are unsure which to start, semaglutide vs tirzepatide walks through the on-label comparison most patients actually face.
2. Build the lifestyle scaffolding. A protein floor of roughly 1.6 g/kg body weight per day (protein intake for weight loss), resistance training two to three times per week, and 7-plus hours of sleep is the foundation that every weight-loss drug builds on. Muscle preservation matters — roughly 20 to 30 percent of the weight lost on high-magnitude GLP-1 drugs is lean mass (preserve muscle during weight loss).
3. Get baseline labs and BMI/waist documented now. A recent lipid panel, HbA1c, TSH, comprehensive metabolic panel, and — for readers over age 40 — a DEXA scan create the record most prior-authorization systems want. A baseline is required before any future intensification decision.
4. Do NOT buy compounded CagriSema. See the safety-warning section above. The gray-market picture for “CagriSema” and “cagrilintide” in 2026 is unsafe, illegal in the sense that it operates outside 503A/503B rules, and does not deliver the drug the REDEFINE-1 trial studied.

Bottom line

CagriSema will likely be the highest-magnitude weight-loss injectable available through 2027 pending retatrutide approval, and the REDEFINE-1 topline of roughly 22.7 percent is real. But the incremental benefit over Wegovy or Zepbound may not justify the wait or the cost for readers whose target is 10 to 15 percent loss. If you are on a current GLP-1 and doing well, keep going; if you are plateaued short of your goal and need more than 20 percent, CagriSema — when approved, and only from a legitimate pharmacy — will be worth the conversation with your obesity-medicine clinician. For the full 2026 prescription weight loss medications landscape and the honest comparison of every currently-approved option, that pillar is the next place to read.